RT Journal Article SR Electronic T1 Causal effects of serum levels of n-3 or n-6 polyunsaturated fatty acids on coronary artery disease: Mendelian randomization study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.10.18.20214791 DO 10.1101/2020.10.18.20214791 A1 Sehoon Park A1 Soojin Lee A1 Yaerim Kim A1 Yeonhee Lee A1 Min Woo Kang A1 Kwangsoo Kim A1 Yong Chul Kim A1 Seung Seok Han A1 Hajeong Lee A1 Jung Pyo Lee A1 Kwon Wook Joo A1 Chun Soo Lim A1 Yon Su Kim A1 Dong Ki Kim YR 2020 UL http://medrxiv.org/content/early/2020/10/20/2020.10.18.20214791.abstract AB Background Additional studies on the causal effects of 3-n and 6-n polyunsaturated fatty acids (PUFAs) on the risk of coronary artery disease (CAD) are warranted.Methods This Mendelian randomization (MR) study utilized a genetic instrument developed from previous genome-wide association studies for various serum 3-n and 6-n PUFA levels. First, we calculated the allele scores for genetic predisposition of PUFAs in individuals of European ancestry in the UK Biobank data (N=337,129). The allele score-based MR was obtained by regressing the allele scores to CAD risks. Second, summary-level MR was performed with the CARDIoGRAMplusC4D data for CAD (N=184,305). The inverse variance-weighted or Wald ratio method was the main analysis for the summary-level MR, and when multiple single nucleotide polymorphisms were utilized (e.g., linoleic acid), MR-Egger and weighted median methods were implemented as sensitivity analyses.Results Higher genetically predicted eicosapentaenoic acid and dihomo-gamma-linolenic acid levels were significantly associated with a lower risk of CAD both in the allele-score-based and summary-level MR analyses. Higher allele scores for linoleic acid level were significantly associated with lower CAD risks, and in the summary-level MR, the causal estimates by the MR-Egger and weighted median methods also indicated that higher linoleic acid levels cause a lower risk of CAD. Arachidonic acid was the 6-n PUFA that showed significant causal estimates for a higher risk of CAD. Higher docosapentaenoic acid and adrenic acid levels showed inconsistent findings in the MR analysis results.Conclusions This study supports the causal effects of certain 3-n and 6-n PUFA types on the risk of CAD.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementThis work was supported by a grant from SNU R&DB Foundation (800-20190571) of the Seoul National University, Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review boards of Seoul National University Hospital (No. E-2070-048-1140) and the UK Biobank consortium (application No. 53799).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study used the data from the UK Biobank consortium, and the approach was approved by the organization (application number: 53799). The summary statistics for the two-sample MR have been provided by the GIANT and the CKDGen consortia.